First Oral Targeted CSU Therapy Clears EC: What Comes Next

Novartis has secured European Commission approval for Rhapsido (remibrutinib), positioning the oral BTK inhibitor as the first targeted therapy in its class approved for chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1-antihistamine treatment. For QA and regulatory teams across Europe, the approval triggers a familiar set of post-authorisation obligations under EMA frameworks, while manufacturing functions face the near-term pressure of scaling a BTKi for a patient population estimated at nearly 4 million in Europe alone, more than half of whom remain symptomatic on conventional antihistamine therapy.

Rhapsido received a positive CHMP opinion in February 2026 before the EC decision formalised market access. The approval is supported by data from the REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) Phase III trials, two identically designed, global, randomised, double-blind, placebo-controlled studies enrolling 925 patients. Remibrutinib demonstrated superiority over placebo in change from baseline for itch, hives, and weekly urticaria activity at Week 12, with improvements observed as early as Week 1. The safety profile showed no liver safety concerns; the most common adverse events at incidence of 3% or greater were nasopharyngitis, bleeding, headache, nausea, and abdominal pain. Notably, the approved label carries no requirement for laboratory monitoring, a feature with direct implications for pharmacovigilance planning and risk management documentation under EMA post-approval commitments.

Mechanism and pipeline context: Remibrutinib is a highly selective oral BTK inhibitor that blocks the BTK pathway involved in histamine release, the primary driver of wheals and angioedema in CSU. Novartis has disclosed positive topline results for remibrutinib in chronic inducible urticaria across three prevalent subtypes in the pivotal Phase III RemIND trial, and the compound is under investigation in hidradenitis suppurativa and food allergy. Remibrutinib is also approved in the US and China for CSU in patients with inadequate H1-antihistamine response. The breadth of the development programme signals that manufacturing scale-up decisions made now will need to accommodate multiple potential indications across global supply chains.

Rhapsido is included in the 2026 International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria, recommended for all patients who remain symptomatic after H1-antihistamine treatment. Prof. Dr. med. Martin Metz, Deputy Director, Institute of Allergology, Charite Universitatsmedizin Berlin, noted that the approval offers fast relief by blocking a key immune pathway and may help a broad range of patients achieve significant disease control. Source: Novartis press release via GlobeNewswire, April 27, 2026.